
zzso zzso is a potent inhibitor of zzso zzso that zzso the transport resistance seen with zzso and has a wide spectrum of zzso zzso A total of 18 patients with advanced cancer were treated in a clinical and pharmacological phase I trial with zzso given as a continuous zzso intravenous zzso zzso zzso and zzso were the zzso zzso at the maximum tolerated dose of 50 zzso per 120 h (10 zzso per day for 5 zzso There was one septic death associated with zzso Other zzso were mild zzso mild zzso and zzso raised serum zzso zzso zzso relationships between the dose given and the zzso of plasma zzso and the zzso plasma level were zzso zzso although weak, relationships between the percentage of change in zzso and zzso and both the zzso and zzso plasma level of zzso were also zzso No objective zzso responses were seen, although six patients had stable zzso The recommended phase II dose for a continuous infusion of zzso is 40 zzso per 120 zzso 

